Tabata Sakiko, Higuchi Tomoaki, Tatsukawa Seishiro, Narimatsu Kazuyuki, Takeo Hiroaki, Matsukuma Susumu, Ito Toshimitsu
Department of Internal Medicine, Japan Self Defense Forces Central Hospital, Japan.
Department of Pathology, Japan Self Defense Forces Central Hospital, Japan.
Intern Med. 2019 Nov 15;58(22):3313-3318. doi: 10.2169/internalmedicine.2989-19. Epub 2019 Jul 10.
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder, and only a few cases have been reported to be complicated with autoimmune hemolytic anemia (AIHA). A 43-year-old man who presented with multiple swollen lymph nodes was diagnosed with iMCD. He was also diagnosed with AIHA based on laboratory findings, including the results of a bone marrow aspiration study. The patient was treated with tocilizumab; however, the effect was limited, probably due to anti-drug antibodies. Tocilizumab was therefore switched to rituximab, and his anemia was improved. Complication with AIHA should be carefully considered when iMCD patients present with severe anemia.
特发性多中心Castleman病(iMCD)是一种罕见的淋巴增殖性疾病,仅有少数病例报告并发自身免疫性溶血性贫血(AIHA)。一名43岁出现多处淋巴结肿大的男性被诊断为iMCD。基于实验室检查结果,包括骨髓穿刺研究结果,他也被诊断为AIHA。该患者接受了托珠单抗治疗;然而,效果有限,可能是由于抗药物抗体。因此将托珠单抗换为利妥昔单抗,他的贫血症状得到改善。当iMCD患者出现严重贫血时,应仔细考虑是否并发AIHA。